pharmaphorum July 23, 2024
German pain medicines specialist Grünenthal has dipped another toe in the M&A waters with a $250 million agreement to buy US drugmaker Valinor Pharma.
The deal is essentially a move to take control of Movantik (naloxegol), which is indicated for the treatment of one of the most prominent side effects of opioid analgesics – constipation – in adult patients with chronic non-cancer pain. The product made $200 million in US sales last year.
Grünenthal already owns rights to Movantik in the EU – where it is sold as Movantig – under the terms of an earlier deal with Japan’s Kyowa Kirin, which saw it take majority rights to 13 mature medicines. The agreement initially created a joint venture, 51% owned...
Today's Sponsors
Today's Sponsor